Home » Newsletters » BioWorld Science

BioWorld Science

July 5, 2021

View Archived Issues

Identification of a vitamin D3 analogue inducing SREBP degradation without calcemic action

Results of phase I dose-escalation study of MVC-COV-1901 SARSCoV-2 vaccine candidate

ALICE study data support iadademstat with azacitidine in acute myeloid leukemia

Washington University reports dosimetry data for brain PET radiotracer [11C]CS1P1

Arrowhead voluntarily pauses phase I/II study of ARO-ENaC in CF

Sanofi initiates early clinical studies of SAR-444245

Genzyme patents new CFTR modulators

Omeros divulges new MASP2 inhibitors

Chinese researchers identify new CDK9 inhibitors

Sichuan Haisco Pharmaceutical identifies new ENPP2 inhibitors

Intestinal MYC modulates weight-related metabolic dysfunction

Beijing Tuojie Biopharmaceutical patents CaSR agonists

Initiation of phase II trial of Hepalatide in chronic hepatitis B

Amgen starts phase I study of AMG-609 in NAFLD

Pluripotent stem cell-derived CECs for the treatment of corneal dystrophies

Patient enrollment begins in phase II study of ADR-001 in severe pneumonia due to COVID-19

Sperogenix to develop Abbisko's ABSK-021 for rare neurological diseases in China

GNT-0003 restores UGT1A1 expression in patients with Crigler-Najjar syndrome

Phase Ib data presented for ulixertinib plus palbociclib in advanced solid tumors

SHR-1314 studied in phase II/III trial for active ankylosing spondylitis

Initiation of phase II study of HA-121-28 in advanced biliary tract cancer

Transcenta reports antitumor responses with TST-001 in gastric cancer

DPP3 is a marker of severity in heart failure

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...